Patents by Inventor Andrew Protter

Andrew Protter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF PROMOTING OSTEOGENESIS
    Publication number: 20080108658
    Abstract: The invention is directed to methods of bone healing by administering a p38 MAP kinase inhibitor. The invention is directed to methods of treating bone fractures, bone diseases, bone grafting, especially enhancing bone healing following facial reconstruction, maxillary reconstruction, mandibular reconstruction or tooth extraction, enhancing long bone extension, enhancing prosthetic ingrowth, and increasing bone synostosis by administering a p38 MAP kinase inhibitor.
    Type: Application
    Filed: September 11, 2007
    Publication date: May 8, 2008
    Inventors: Andrew Protter, David Liu, Patrick O'Connor
  • Treatment of pain by inhibition of p38 map kinase
    Publication number: 20080039461
    Abstract: The present invention relates to methods for the prevention or treatment of pain by the inhibition of p38 MAP kinase.
    Type: Application
    Filed: December 28, 2006
    Publication date: February 14, 2008
    Inventors: Andrew Protter, Camilla Svensson, Tony Yaksh, Barbara Cordell, Sundeep Dugar
  • Recombinant fibroblast growth factor analogs
    Patent number: 7186526
    Abstract: The DNA sequences encoding analogs of human acidic and basic fibroblast growth factors (FGF) can be recombinantly expressed to obtain practical amounts of proteins useful in effecting both pathologies related to persistent angiogenesis and wound healing and related tissue repair.
    Type: Grant
    Filed: June 13, 2005
    Date of Patent: March 6, 2007
    Assignee: Scios, Inc.
    Inventors: John C. Fiddes, Judith A. Abraham, Andrew Protter
  • Treatment of osteolytic lesions associated with multiple myeloma by inhibition of p38 map kinase
    Publication number: 20060058296
    Abstract: The present invention provides a method to treat osteolytic lesions associated with multiple myeloma by the administration of one or more p38 MAP kinase inhibitors.
    Type: Application
    Filed: August 19, 2005
    Publication date: March 16, 2006
    Applicant: Scios, Inc.
    Inventors: Linda Higgins, Andrew Protter
  • Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
    Publication number: 20060052390
    Abstract: The present invention provides a method to treat multiple myeloma by the co-administration of one or more p38 MAP kinase inhibitors with one or more proteosome inhibitors.
    Type: Application
    Filed: August 19, 2005
    Publication date: March 9, 2006
    Applicant: Scios, Inc.
    Inventors: George Schreiner, Andrew Protter, Linda Higgins
  • Recombinant fibroblast growth factor analogs
    Publication number: 20050227329
    Abstract: The DNA sequences encoding analogs of human acidic and basic fibroblast growth factors (FGF) can be recombinantly expressed to obtain practical amounts of proteins useful in effecting both pathologies related to persistent angiogenesis and wound healing and related tissue repair.
    Type: Application
    Filed: June 13, 2005
    Publication date: October 13, 2005
    Inventors: John Fiddes, Judith Abraham, Andrew Protter
  • Recombinant fibroblast growth factors
    Publication number: 20030040042
    Abstract: The DNA sequences encoding analogs of human acidic and basic fibroblast growth factors (FGF) can be recombinantly expressed to obtain practical amounts of proteins useful in effecting both pathologies related to persistent angiogenesis and wound healing and related tissue repair.
    Type: Application
    Filed: July 9, 2001
    Publication date: February 27, 2003
    Inventors: John C. Fiddes, Judith A. Abraham, Andrew Protter
  • Human basic fibroblast growth factor analog
    Patent number: 6294359
    Abstract: The DNA sequences encoding analogs of human acidic and basic fibroblast growth factors (FGF) can be recombinantly expressed to obtain practical amounts of proteins useful in effecting both pathologies related to persistent angiogenesis and wound healing and related tissue repair.
    Type: Grant
    Filed: June 16, 1998
    Date of Patent: September 25, 2001
    Assignee: Scios Inc.
    Inventors: John C. Fiddes, Judith A. Abraham, Andrew Protter